BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30295244)

  • 1. [Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].
    Liu YF; He PC; Zhang M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1317-1322. PubMed ID: 30295244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia].
    Lin GQ; Zhang YM; Kang LQ; Yu L; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):829-835. PubMed ID: 33190440
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
    Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
    Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
    She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
    Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
    Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].
    Zhu XY; Liu X; Wang XB; Wang AY; Wang M; Liu NN; You FT; Pan GF; Yang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1367-1375. PubMed ID: 32798428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.
    Lion E; Smits EL; Berneman ZN; Van Tendeloo VF
    Leuk Res; 2009 Apr; 33(4):539-46. PubMed ID: 18845337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
    Benson DM; Bakan CE; Mishra A; Hofmeister CC; Efebera Y; Becknell B; Baiocchi RA; Zhang J; Yu J; Smith MK; Greenfield CN; Porcu P; Devine SM; Rotem-Yehudar R; Lozanski G; Byrd JC; Caligiuri MA
    Blood; 2010 Sep; 116(13):2286-94. PubMed ID: 20460501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
    Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
    Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.
    Lee JY; Park S; Kim DC; Yoon JH; Shin SH; Min WS; Kim HJ
    J Clin Immunol; 2013 May; 33(4):826-37. PubMed ID: 23404187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Interaction Regulates BCL2, KI67, BAX, and CASP3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid Leukemia.
    Soltani M; Vosoughi M; Ganjalikhani-Hakemi M; Shapoorian H; Beshkar P; Eskandari N; Ghezelbash B
    Iran J Allergy Asthma Immunol; 2023 Oct; 22(5):495-503. PubMed ID: 38085150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inflammatory factors promote the expression of PD-L1 in Tca8113].
    Lu LB; Chen J; Feng Y; Zhou CC; Zhang P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Jan; 44(1):42-5. PubMed ID: 23600206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect].
    Wang ZH; Liu HH; Ma N; Wang LH; Liu W; Tang B; Qiu ZX; Cen XN; Ren HY; Dong YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1559-1564. PubMed ID: 30295284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.